Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome

Journal of Endocrinological Investigation

Volumn 32, Issue 8, 2009, Pages 695-700

  Targher, G ^a   Solagna, E ^a   Tosi, F ^a   Castello, R ^a   Spiazzi, G ^a   Zoppini, G ^a   Muggeo, M ^a   Day, C P ^b   Moghetti, P ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Insulin resistance; Liver fat; Non alcoholic fatty liver disease; Polycystic ovary syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; ANDROSTENEDIONE; ASPARTATE AMINOTRANSFERASE; FOLLITROPIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYPROGESTERONE; INSULIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; TESTOSTERONE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY FAT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GONADORELIN TEST; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; NONALCOHOLIC FATTY LIVER; OBESITY; OVARY POLYCYSTIC DISEASE; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; OBESITY; POLYCYSTIC OVARY SYNDROME; RETROSPECTIVE STUDIES;

EID: 70450150499     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03345743     Document Type: Article

References (31)

1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999, 84: 4006-4011 (Pubitemid 30644187)
2. Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000, 85: 2434-2438
3. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004, 89: 2745-2749 (Pubitemid 38766360)
4. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992, 41: 1257-1266
5. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998, 83: 2694-2698 (Pubitemid 28493762)
6. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005, 83: 1454-1460 (Pubitemid 40615820)
7. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008, 48 (Suppl 1): S104-12.
8. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006, 40 (Suppl 1): S5-10.
9. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28: 27-38.
10. Schwimmer JB, Khorram O, Chiu V, Schwimmer WB. Abnormal aminotransferase activity in women with polycystic ovary syndrome. Fertil Steril 2005, 83: 494-497
11. Setji TL, Holland ND, Sanders LL, Pereira KC, Diehl AM, Brown AJ. Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006, 91: 1741-1747
12. Cerda C, Pérez-Ayuso RM, Riquelme A, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 2007, 47: 412-417 (Pubitemid 47176161)
13. Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol 2007, 5: 496-501.
14. Radziuk J. Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab 2000, 85: 4426-4433
15. Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000, 85: 139-146 (Pubitemid 32268804)
16. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004, 81: 19-25.
17. Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006, 91: 4237-4245
18. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002, 137: 1-10.
19. Moghetti P, Tosi F, Castello R, et al. The insulin resistance in women with hyperandrogenism is partially reversed by anti-androgen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 1996, 81: 952-960 (Pubitemid 26083953)
20. Pasquali R, Patton L, Pocognoli P, Cognigni GE, Gambineri A. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome. J Clin Endocrinol Metab 2007, 92: 4208-4217 (Pubitemid 350074733)
21. Moghetti P, Castello R, Negri C, et al. Insulin infusion amplifies 17 alpha-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J Clin Endocrinol Metab 1996, 81: 881-886 (Pubitemid 26083940)
22. Zanolin ME, Tosi F, Zoppini G, et al. Clustering of cardiovascular risk factors associated with the insulin resistance syndrome: assessment by principal component analysis in young hyperandrogenic women. Diabetes Care 2006, 29: 372-378 (Pubitemid 44106521)
23. Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 2008, 134: 1369-1375 (Pubitemid 351615354)
24. Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 2006, 22: 437-443 (Pubitemid 44774047)
25. Day CP. From fat to inflammation. Gastroenterology 2006, 130: 207-210
26. Targher G, Bertolini L, Rodella S, et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) 2008, 16: 1394-1399 (Pubitemid 351770539)
27. Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008, 27: 412-421
28. Targher G, Arcaro G. Nonalcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007, 191: 235-240 (Pubitemid 46400718)
29. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44: 865-873
30. Targher G, Bertolini L, Poli F, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005, 54: 3541-3546 (Pubitemid 43334347)
31. Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007, 30: 2119-2121 (Pubitemid 47219432)